Key clinical point: Oral azacitidine (OA) maintenance had a manageable safety profile in patients with newly diagnosed acute myeloid leukemia (AML) who attained the first complete remission (CR) or CR with incomplete blood count recovery (CRi) after induction chemotherapy (IC). However, blood count monitoring for at least the first 2 treatment cycles is recommended.

Major finding: Gastrointestinal (91% vs. 62%) and hematologic (66% vs. 47%) adverse events were common with OA vs. placebo. Adverse events were mostly manageable with dose interruptions (43%) or reductions (16%) and infrequently led to OA discontinuation (13%).

Study details: This safety analysis of the QUAZAR AML-001 trial included 469 patients with newly diagnosed AML with intermediate- or poor-risk cytogenetics who attained the first CR/CRi after IC, randomly assigned to receive either 300 mg OA (n = 236) or placebo (n = 233).

Disclosures: This study was funded by Celgene, a Bristol Myers Squibb Company. Some investigators, including the lead author, reported ties with various pharmaceutical companies including Celgene and Bristol Myers Squibb.

Source: Ravandi F et al. J Hematol Oncol. 2021 Aug 28. doi: 10.1186/s13045-021-01142-x.

Key clinical point: Oral azacitidine (OA) maintenance had a manageable safety profile in patients with newly diagnosed acute myeloid leukemia (AML) who attained the first complete remission (CR) or CR with incomplete blood count recovery (CRi) after induction chemotherapy (IC). However, blood count monitoring for at least the first 2 treatment cycles is recommended.

Major finding: Gastrointestinal (91% vs. 62%) and hematologic (66% vs. 47%) adverse events were common with OA vs. placebo. Adverse events were mostly manageable with dose interruptions (43%) or reductions (16%) and infrequently led to OA discontinuation (13%).

Study details: This safety analysis of the QUAZAR AML-001 trial included 469 patients with newly diagnosed AML with intermediate- or poor-risk cytogenetics who attained the first CR/CRi after IC, randomly assigned to receive either 300 mg OA (n = 236) or placebo (n = 233).

Disclosures: This study was funded by Celgene, a Bristol Myers Squibb Company. Some investigators, including the lead author, reported ties with various pharmaceutical companies including Celgene and Bristol Myers Squibb.

Source: Ravandi F et al. J Hematol Oncol. 2021 Aug 28. doi: 10.1186/s13045-021-01142-x.

Key clinical point: Oral azacitidine (OA) maintenance had a manageable safety profile in patients with newly diagnosed acute myeloid leukemia (AML) who attained the first complete remission (CR) or CR with incomplete blood count recovery (CRi) after induction chemotherapy (IC). However, blood count monitoring for at least the first 2 treatment cycles is recommended.

Major finding: Gastrointestinal (91% vs. 62%) and hematologic (66% vs. 47%) adverse events were common with OA vs. placebo. Adverse events were mostly manageable with dose interruptions (43%) or reductions (16%) and infrequently led to OA discontinuation (13%).

Study details: This safety analysis of the QUAZAR AML-001 trial included 469 patients with newly diagnosed AML with intermediate- or poor-risk cytogenetics who attained the first CR/CRi after IC, randomly assigned to receive either 300 mg OA (n = 236) or placebo (n = 233).

Disclosures: This study was funded by Celgene, a Bristol Myers Squibb Company. Some investigators, including the lead author, reported ties with various pharmaceutical companies including Celgene and Bristol Myers Squibb.

Source: Ravandi F et al. J Hematol Oncol. 2021 Aug 28. doi: 10.1186/s13045-021-01142-x.

Key clinical point: Low-intensity treatment with low-dose cytarabine (LD-AC) combined with cladribine offered therapeutic benefit with an acceptable safety profile in elderly patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy.

Major finding: Rates of overall response and 56-day mortality were 54.0% and 20.5%, respectively. The median overall survival was 6.9 months (95% CI 4.9-9.6) and superior in patients who achieved an objective response (hazard ratio [HR] 0.04; P < .0001) or partial remission (HR 0.31; P = .0002) compared to nonresponders.

Study details: Findings are from a prospective analysis of 117 elderly patients (age, 60 years or older) with AML with poor performance status or a high comorbidity index treated with frontline LD-AC and cladribine.

Disclosures: This study was supported by the Institute of Hematology and Transfusion Medicine in Warsaw and Polish Adult Leukemia Group. The authors declared no conflicts of interest.

Source: Budziszewska BK et al. Cancers. 2021 Aug 20. doi: 10.3390/cancers13164189.

Key clinical point: Low-intensity treatment with low-dose cytarabine (LD-AC) combined with cladribine offered therapeutic benefit with an acceptable safety profile in elderly patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy.

Major finding: Rates of overall response and 56-day mortality were 54.0% and 20.5%, respectively. The median overall survival was 6.9 months (95% CI 4.9-9.6) and superior in patients who achieved an objective response (hazard ratio [HR] 0.04; P < .0001) or partial remission (HR 0.31; P = .0002) compared to nonresponders.

Study details: Findings are from a prospective analysis of 117 elderly patients (age, 60 years or older) with AML with poor performance status or a high comorbidity index treated with frontline LD-AC and cladribine.

Disclosures: This study was supported by the Institute of Hematology and Transfusion Medicine in Warsaw and Polish Adult Leukemia Group. The authors declared no conflicts of interest.

Source: Budziszewska BK et al. Cancers. 2021 Aug 20. doi: 10.3390/cancers13164189.

Key clinical point: Low-intensity treatment with low-dose cytarabine (LD-AC) combined with cladribine offered therapeutic benefit with an acceptable safety profile in elderly patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy.

Major finding: Rates of overall response and 56-day mortality were 54.0% and 20.5%, respectively. The median overall survival was 6.9 months (95% CI 4.9-9.6) and superior in patients who achieved an objective response (hazard ratio [HR] 0.04; P < .0001) or partial remission (HR 0.31; P = .0002) compared to nonresponders.

Study details: Findings are from a prospective analysis of 117 elderly patients (age, 60 years or older) with AML with poor performance status or a high comorbidity index treated with frontline LD-AC and cladribine.

Disclosures: This study was supported by the Institute of Hematology and Transfusion Medicine in Warsaw and Polish Adult Leukemia Group. The authors declared no conflicts of interest.

Source: Budziszewska BK et al. Cancers. 2021 Aug 20. doi: 10.3390/cancers13164189.

Key clinical point: Gemtuzumab ozogamicin (GO) showed superior survival outcomes in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) than non-GO therapy, but higher dose increased the risk for early death.

Major finding: GO vs. non-GO arm showed improved overall survival (hazard ratio [HR], 0.86; P = .003), event-free survival (HR, 0.86; P = .015), and relapse-free survival (HR, 0.83; P = .001). However, GO vs. non-GO was associated with an increased risk for early death at a dose of 6 mg/m² or higher (relative risk [RR] 2.01; P = .005), hepatic-related adverse effects (RR 1.29; P = .02), and bleeding (RR 1.13; P = .018).

Study details: Findings are from a meta-analysis of 15 randomized controlled trials and 15 retrospective studies that compared GO (n = 4,768) with non-GO (n = 6,466) therapies in 11,234 patients with AML (n = 11,105) and high-risk MDS (n = 129).

Disclosures: This study was supported by the Chinese National Major Project for New Drug Innovation, the National Natural Science Foundation of China, Shenzhen Science and Technology Foundation, and Shenzhen Key Laboratory Foundation. The authors declared no conflicts of interest.

Source: Xu Q et al. Front Immunol. 2021 Aug 16. doi: 10.3389/fimmu.2021.683595.

Key clinical point: Gemtuzumab ozogamicin (GO) showed superior survival outcomes in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) than non-GO therapy, but higher dose increased the risk for early death.

Major finding: GO vs. non-GO arm showed improved overall survival (hazard ratio [HR], 0.86; P = .003), event-free survival (HR, 0.86; P = .015), and relapse-free survival (HR, 0.83; P = .001). However, GO vs. non-GO was associated with an increased risk for early death at a dose of 6 mg/m² or higher (relative risk [RR] 2.01; P = .005), hepatic-related adverse effects (RR 1.29; P = .02), and bleeding (RR 1.13; P = .018).

Study details: Findings are from a meta-analysis of 15 randomized controlled trials and 15 retrospective studies that compared GO (n = 4,768) with non-GO (n = 6,466) therapies in 11,234 patients with AML (n = 11,105) and high-risk MDS (n = 129).

Disclosures: This study was supported by the Chinese National Major Project for New Drug Innovation, the National Natural Science Foundation of China, Shenzhen Science and Technology Foundation, and Shenzhen Key Laboratory Foundation. The authors declared no conflicts of interest.

Source: Xu Q et al. Front Immunol. 2021 Aug 16. doi: 10.3389/fimmu.2021.683595.

Key clinical point: Gemtuzumab ozogamicin (GO) showed superior survival outcomes in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) than non-GO therapy, but higher dose increased the risk for early death.

Major finding: GO vs. non-GO arm showed improved overall survival (hazard ratio [HR], 0.86; P = .003), event-free survival (HR, 0.86; P = .015), and relapse-free survival (HR, 0.83; P = .001). However, GO vs. non-GO was associated with an increased risk for early death at a dose of 6 mg/m² or higher (relative risk [RR] 2.01; P = .005), hepatic-related adverse effects (RR 1.29; P = .02), and bleeding (RR 1.13; P = .018).

Study details: Findings are from a meta-analysis of 15 randomized controlled trials and 15 retrospective studies that compared GO (n = 4,768) with non-GO (n = 6,466) therapies in 11,234 patients with AML (n = 11,105) and high-risk MDS (n = 129).

Disclosures: This study was supported by the Chinese National Major Project for New Drug Innovation, the National Natural Science Foundation of China, Shenzhen Science and Technology Foundation, and Shenzhen Key Laboratory Foundation. The authors declared no conflicts of interest.

Source: Xu Q et al. Front Immunol. 2021 Aug 16. doi: 10.3389/fimmu.2021.683595.

Key clinical point: Enasidenib was associated with superior overall survival (OS) compared to standard of care (SoC) therapies in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation who were ineligible for hematopoietic stem cell transplantation (HSCT).

Major finding: Enasidenib vs. SoC was associated with a significantly longer OS (hazard ratio 0.67; 95% CI 0.47-0.97).

Study details: Findings are from a propensity score-matching analysis including adult patients with R/R AML with an IDH2 mutation ineligible for HSCT treated with enasidenib (n=195) from the AG221 C-001 trial or SoC therapies (n=78) from the French Chart Review study.

Disclosures: This study was sponsored and funded by Bristol Myers Squibb Some investigators, including the lead author, reported ties with various pharmaceutical companies, including Bristol Myers Squibb.

Source: de Botton S et al. Cancer Med. 2021 Aug 24. doi: 10.1002/cam4.4182.

Key clinical point: Enasidenib was associated with superior overall survival (OS) compared to standard of care (SoC) therapies in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation who were ineligible for hematopoietic stem cell transplantation (HSCT).

Major finding: Enasidenib vs. SoC was associated with a significantly longer OS (hazard ratio 0.67; 95% CI 0.47-0.97).

Study details: Findings are from a propensity score-matching analysis including adult patients with R/R AML with an IDH2 mutation ineligible for HSCT treated with enasidenib (n=195) from the AG221 C-001 trial or SoC therapies (n=78) from the French Chart Review study.

Disclosures: This study was sponsored and funded by Bristol Myers Squibb Some investigators, including the lead author, reported ties with various pharmaceutical companies, including Bristol Myers Squibb.

Source: de Botton S et al. Cancer Med. 2021 Aug 24. doi: 10.1002/cam4.4182.

Key clinical point: Enasidenib was associated with superior overall survival (OS) compared to standard of care (SoC) therapies in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation who were ineligible for hematopoietic stem cell transplantation (HSCT).

Major finding: Enasidenib vs. SoC was associated with a significantly longer OS (hazard ratio 0.67; 95% CI 0.47-0.97).

Study details: Findings are from a propensity score-matching analysis including adult patients with R/R AML with an IDH2 mutation ineligible for HSCT treated with enasidenib (n=195) from the AG221 C-001 trial or SoC therapies (n=78) from the French Chart Review study.

Disclosures: This study was sponsored and funded by Bristol Myers Squibb Some investigators, including the lead author, reported ties with various pharmaceutical companies, including Bristol Myers Squibb.

Source: de Botton S et al. Cancer Med. 2021 Aug 24. doi: 10.1002/cam4.4182.

Key clinical point: The administration of decitabine in alternating cycles with sapacitabine vs. decitabine monotherapy did not significantly improve outcomes in older patients with newly diagnosed acute myeloid leukemia (AML) who were unfit or chose not to receive intensive induction chemotherapy.

Major finding: The median overall survival (5.9 months vs. 5.7 months; P = .8902) and rates of complete remission (16.6% vs. 10.8%; P = .1468) were not significantly different in patients receiving decitabine plus sapacitabine vs. decitabine monotherapy.

Study details: Findings are from the phase 3 SEAMLESS trial including 482 elderly patients (age, 70 years or older) with newly diagnosed AML unsuitable or unwilling for intensive induction chemotherapy. Patients were randomly assigned to receive either decitabine in alternating cycles with sapacitabine or decitabine monotherapy.

Disclosures: This study was sponsored by Cyclacel Limited (Dundee, Scotland, United Kingdom). The lead author reported research grants and honoraria from various sources. Other authors reported ties with various pharmaceutical companies including Cyclacel.

Source: Kantarjian HM et al. Cancer. 2021 Aug 23. doi: 10.1002/cncr.33828.

Key clinical point: The administration of decitabine in alternating cycles with sapacitabine vs. decitabine monotherapy did not significantly improve outcomes in older patients with newly diagnosed acute myeloid leukemia (AML) who were unfit or chose not to receive intensive induction chemotherapy.

Major finding: The median overall survival (5.9 months vs. 5.7 months; P = .8902) and rates of complete remission (16.6% vs. 10.8%; P = .1468) were not significantly different in patients receiving decitabine plus sapacitabine vs. decitabine monotherapy.

Study details: Findings are from the phase 3 SEAMLESS trial including 482 elderly patients (age, 70 years or older) with newly diagnosed AML unsuitable or unwilling for intensive induction chemotherapy. Patients were randomly assigned to receive either decitabine in alternating cycles with sapacitabine or decitabine monotherapy.

Disclosures: This study was sponsored by Cyclacel Limited (Dundee, Scotland, United Kingdom). The lead author reported research grants and honoraria from various sources. Other authors reported ties with various pharmaceutical companies including Cyclacel.

Source: Kantarjian HM et al. Cancer. 2021 Aug 23. doi: 10.1002/cncr.33828.

Key clinical point: The administration of decitabine in alternating cycles with sapacitabine vs. decitabine monotherapy did not significantly improve outcomes in older patients with newly diagnosed acute myeloid leukemia (AML) who were unfit or chose not to receive intensive induction chemotherapy.

Major finding: The median overall survival (5.9 months vs. 5.7 months; P = .8902) and rates of complete remission (16.6% vs. 10.8%; P = .1468) were not significantly different in patients receiving decitabine plus sapacitabine vs. decitabine monotherapy.

Study details: Findings are from the phase 3 SEAMLESS trial including 482 elderly patients (age, 70 years or older) with newly diagnosed AML unsuitable or unwilling for intensive induction chemotherapy. Patients were randomly assigned to receive either decitabine in alternating cycles with sapacitabine or decitabine monotherapy.

Disclosures: This study was sponsored by Cyclacel Limited (Dundee, Scotland, United Kingdom). The lead author reported research grants and honoraria from various sources. Other authors reported ties with various pharmaceutical companies including Cyclacel.

Source: Kantarjian HM et al. Cancer. 2021 Aug 23. doi: 10.1002/cncr.33828.

Key clinical point: Patients with psoriatic arthritis (PsA) performed poorly in all dimensions of the European Quality of Life (EQ-5D) scoring of quality of life (QoL) as compared with the general population, thus reflecting the detrimental effect of PsA on QoL.

Major finding: Overall, 87.3% and 69.8% of patients with PsA experienced pain/discomfort and anxiety/depression, respectively. Patients with PsA presented worse results in all dimensions of the EQ-5D scale and had a lower mean QoL score compared to the general population (0.651 vs. 0.793; P < .001) with worsened QoL in patients with concomitant use of nonsteroidal anti-inflammatory drugs (P = .035) and comorbidities (P = .003).

Study details: Findings are from a cross-sectional study including 212 adult patients with PsA from a single-center pharmacy in Minas Gerais, Brazil.

Disclosures: This study was supported by Minas Gerais Research Support Foundation and National Council for Scientific and Technological Development. Several of the authors declared receiving educational scholarships, grants, or personal fees from several sources.

Source: Moraes FA et al. Value Health Reg Issues. 2021 Aug 12. doi: 10.1016/j.vhri.2021.06.003.

Key clinical point: Patients with psoriatic arthritis (PsA) performed poorly in all dimensions of the European Quality of Life (EQ-5D) scoring of quality of life (QoL) as compared with the general population, thus reflecting the detrimental effect of PsA on QoL.

Major finding: Overall, 87.3% and 69.8% of patients with PsA experienced pain/discomfort and anxiety/depression, respectively. Patients with PsA presented worse results in all dimensions of the EQ-5D scale and had a lower mean QoL score compared to the general population (0.651 vs. 0.793; P < .001) with worsened QoL in patients with concomitant use of nonsteroidal anti-inflammatory drugs (P = .035) and comorbidities (P = .003).

Study details: Findings are from a cross-sectional study including 212 adult patients with PsA from a single-center pharmacy in Minas Gerais, Brazil.

Disclosures: This study was supported by Minas Gerais Research Support Foundation and National Council for Scientific and Technological Development. Several of the authors declared receiving educational scholarships, grants, or personal fees from several sources.

Source: Moraes FA et al. Value Health Reg Issues. 2021 Aug 12. doi: 10.1016/j.vhri.2021.06.003.

Key clinical point: Patients with psoriatic arthritis (PsA) performed poorly in all dimensions of the European Quality of Life (EQ-5D) scoring of quality of life (QoL) as compared with the general population, thus reflecting the detrimental effect of PsA on QoL.

Major finding: Overall, 87.3% and 69.8% of patients with PsA experienced pain/discomfort and anxiety/depression, respectively. Patients with PsA presented worse results in all dimensions of the EQ-5D scale and had a lower mean QoL score compared to the general population (0.651 vs. 0.793; P < .001) with worsened QoL in patients with concomitant use of nonsteroidal anti-inflammatory drugs (P = .035) and comorbidities (P = .003).

Study details: Findings are from a cross-sectional study including 212 adult patients with PsA from a single-center pharmacy in Minas Gerais, Brazil.

Disclosures: This study was supported by Minas Gerais Research Support Foundation and National Council for Scientific and Technological Development. Several of the authors declared receiving educational scholarships, grants, or personal fees from several sources.

Source: Moraes FA et al. Value Health Reg Issues. 2021 Aug 12. doi: 10.1016/j.vhri.2021.06.003.

Key clinical point: Significant improvement in work productivity was observed in a real-world cohort of patients with psoriatic arthritis (PsA) treated with a tumor necrosis factor inhibitor (anti-TNF).

Major finding: At the final follow-up visit, the overall activity impairment decreased from 55.0 ± 21.5 to 16.3 ± 18.2 (P < .001). Moreover, absenteeism, mean presenteeism, and work productivity loss showed significant improvement upon treatment at the 9-month follow-up visit (all P < .001).

Study details: Findings are from a noninterventional, prospective, and observational cohort study including 120 patients with PsA who were receiving anti-TNF treatment.

Disclosures: This study was supported by AbbVie. Some of the authors declared receiving speaker’s fees, consulting fees, or research grants from various sources including AbbVie.

Source: Karadag O et al. Clin Rheumatol. 2021 Sep 3. doi: 10.1007/s10067-021-05893-3.

Key clinical point: Significant improvement in work productivity was observed in a real-world cohort of patients with psoriatic arthritis (PsA) treated with a tumor necrosis factor inhibitor (anti-TNF).

Major finding: At the final follow-up visit, the overall activity impairment decreased from 55.0 ± 21.5 to 16.3 ± 18.2 (P < .001). Moreover, absenteeism, mean presenteeism, and work productivity loss showed significant improvement upon treatment at the 9-month follow-up visit (all P < .001).

Study details: Findings are from a noninterventional, prospective, and observational cohort study including 120 patients with PsA who were receiving anti-TNF treatment.

Disclosures: This study was supported by AbbVie. Some of the authors declared receiving speaker’s fees, consulting fees, or research grants from various sources including AbbVie.

Source: Karadag O et al. Clin Rheumatol. 2021 Sep 3. doi: 10.1007/s10067-021-05893-3.

Key clinical point: Significant improvement in work productivity was observed in a real-world cohort of patients with psoriatic arthritis (PsA) treated with a tumor necrosis factor inhibitor (anti-TNF).

Major finding: At the final follow-up visit, the overall activity impairment decreased from 55.0 ± 21.5 to 16.3 ± 18.2 (P < .001). Moreover, absenteeism, mean presenteeism, and work productivity loss showed significant improvement upon treatment at the 9-month follow-up visit (all P < .001).

Study details: Findings are from a noninterventional, prospective, and observational cohort study including 120 patients with PsA who were receiving anti-TNF treatment.

Disclosures: This study was supported by AbbVie. Some of the authors declared receiving speaker’s fees, consulting fees, or research grants from various sources including AbbVie.

Source: Karadag O et al. Clin Rheumatol. 2021 Sep 3. doi: 10.1007/s10067-021-05893-3.

Key clinical point: Obesity was associated with a higher disease activity and poorer quality of life (QoL) in patients with psoriatic arthritis (PsA), thus emphasizing the need to consider obesity during the management of patients with PsA.

Major finding: Patients with obesity had a significantly higher PsA QoL questionnaire and psychological status measured by the Hospital Anxiety and Depression Scale compared with nonobese patients (P < .001). Even the disease activity index for PsA score was higher in patients with obesity (P < .05), whereas Psoriasis Area and Severity Index was similar between both groups (P = .154).

Study details: Findings are from a cross-sectional study including 1,033 patients with PsA, of which 62.9% of patients were nonobese and 37.1% were obese.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Gok K et al. Rheumatol Int. 2021 Aug 28. doi: 10.1007/s00296-021-04971-8.

Key clinical point: Obesity was associated with a higher disease activity and poorer quality of life (QoL) in patients with psoriatic arthritis (PsA), thus emphasizing the need to consider obesity during the management of patients with PsA.

Major finding: Patients with obesity had a significantly higher PsA QoL questionnaire and psychological status measured by the Hospital Anxiety and Depression Scale compared with nonobese patients (P < .001). Even the disease activity index for PsA score was higher in patients with obesity (P < .05), whereas Psoriasis Area and Severity Index was similar between both groups (P = .154).

Study details: Findings are from a cross-sectional study including 1,033 patients with PsA, of which 62.9% of patients were nonobese and 37.1% were obese.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Gok K et al. Rheumatol Int. 2021 Aug 28. doi: 10.1007/s00296-021-04971-8.

Key clinical point: Obesity was associated with a higher disease activity and poorer quality of life (QoL) in patients with psoriatic arthritis (PsA), thus emphasizing the need to consider obesity during the management of patients with PsA.

Major finding: Patients with obesity had a significantly higher PsA QoL questionnaire and psychological status measured by the Hospital Anxiety and Depression Scale compared with nonobese patients (P < .001). Even the disease activity index for PsA score was higher in patients with obesity (P < .05), whereas Psoriasis Area and Severity Index was similar between both groups (P = .154).

Study details: Findings are from a cross-sectional study including 1,033 patients with PsA, of which 62.9% of patients were nonobese and 37.1% were obese.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Gok K et al. Rheumatol Int. 2021 Aug 28. doi: 10.1007/s00296-021-04971-8.

Key clinical point: Endothelial dysfunction (ED) was inversely correlated with the severity of depressive symptoms in patients with psoriatic arthritis (PsA).

Major finding: Overall, 40% of PsA patients experienced depressive symptoms according to the Hospital Anxiety and Depression Scale (HDS). ED as measured by flow-mediated dilatation was negatively correlated with HDS score (Pearson’s coefficient [ρ] −0.339; P = .016), intensity of pain, and disease activity in PsA score (both ρ, −0.507; P = .001).

Study details: Findings are from a cross-sectional study including 50 patients with PsA between 30 and 75 years of age and without any previous history of heart disease or diabetes.

Disclosures: No information on funding was available. The authors declared no conflicts of interest.

Source: De Lorenzis E et al. Front Med. 2021 Aug 27. doi: 10.3389/fmed.2021.669397.

Key clinical point: Endothelial dysfunction (ED) was inversely correlated with the severity of depressive symptoms in patients with psoriatic arthritis (PsA).

Major finding: Overall, 40% of PsA patients experienced depressive symptoms according to the Hospital Anxiety and Depression Scale (HDS). ED as measured by flow-mediated dilatation was negatively correlated with HDS score (Pearson’s coefficient [ρ] −0.339; P = .016), intensity of pain, and disease activity in PsA score (both ρ, −0.507; P = .001).

Study details: Findings are from a cross-sectional study including 50 patients with PsA between 30 and 75 years of age and without any previous history of heart disease or diabetes.

Disclosures: No information on funding was available. The authors declared no conflicts of interest.

Source: De Lorenzis E et al. Front Med. 2021 Aug 27. doi: 10.3389/fmed.2021.669397.

Key clinical point: Endothelial dysfunction (ED) was inversely correlated with the severity of depressive symptoms in patients with psoriatic arthritis (PsA).

Major finding: Overall, 40% of PsA patients experienced depressive symptoms according to the Hospital Anxiety and Depression Scale (HDS). ED as measured by flow-mediated dilatation was negatively correlated with HDS score (Pearson’s coefficient [ρ] −0.339; P = .016), intensity of pain, and disease activity in PsA score (both ρ, −0.507; P = .001).

Study details: Findings are from a cross-sectional study including 50 patients with PsA between 30 and 75 years of age and without any previous history of heart disease or diabetes.

Disclosures: No information on funding was available. The authors declared no conflicts of interest.

Source: De Lorenzis E et al. Front Med. 2021 Aug 27. doi: 10.3389/fmed.2021.669397.

Key clinical point: Treatment modification was frequently observed in a cohort of patients with psoriatic arthritis (PsA) receiving disease-modifying antirheumatic drugs (DMARD), highlighting the need for more effective therapies.

Major finding: Overall, 57.3% of patients were treated with biologic DMARDs either as monotherapy or in combination with conventional synthetic DMARDs (csDMARD), whereas 37.7% and 4.4% of patients were treated with csDMARDs and targeted synthetic DMARDs, respectively. Treatment modifications in the previous year were reported by 48.4% of patients, with major reasons being lack of efficacy (38%) and remission or major improvement in the disease (14%).

Study details: Findings are from a retrospective observational cross-sectional study including 316 adults with established PsA and psoriasis who received DMARD treatment for at least 183 days in the previous year.

Disclosures: This work was funded by Bristol Myers Squibb, Germany. Some of the authors declared receiving speaker’s fees and compensation for consultancy or board memberships from Bristol Myers Squibb. Dr. Daamen and Dr. Rothnie declared being current or previous employees of Bristol Myers Squibb.

Source: Behrens F et al. Mod Rheumatol. 2021 Aug 26. doi: 10.1080/14397595.2020.1816597.

Key clinical point: Treatment modification was frequently observed in a cohort of patients with psoriatic arthritis (PsA) receiving disease-modifying antirheumatic drugs (DMARD), highlighting the need for more effective therapies.

Major finding: Overall, 57.3% of patients were treated with biologic DMARDs either as monotherapy or in combination with conventional synthetic DMARDs (csDMARD), whereas 37.7% and 4.4% of patients were treated with csDMARDs and targeted synthetic DMARDs, respectively. Treatment modifications in the previous year were reported by 48.4% of patients, with major reasons being lack of efficacy (38%) and remission or major improvement in the disease (14%).

Study details: Findings are from a retrospective observational cross-sectional study including 316 adults with established PsA and psoriasis who received DMARD treatment for at least 183 days in the previous year.

Disclosures: This work was funded by Bristol Myers Squibb, Germany. Some of the authors declared receiving speaker’s fees and compensation for consultancy or board memberships from Bristol Myers Squibb. Dr. Daamen and Dr. Rothnie declared being current or previous employees of Bristol Myers Squibb.

Source: Behrens F et al. Mod Rheumatol. 2021 Aug 26. doi: 10.1080/14397595.2020.1816597.

Key clinical point: Treatment modification was frequently observed in a cohort of patients with psoriatic arthritis (PsA) receiving disease-modifying antirheumatic drugs (DMARD), highlighting the need for more effective therapies.

Major finding: Overall, 57.3% of patients were treated with biologic DMARDs either as monotherapy or in combination with conventional synthetic DMARDs (csDMARD), whereas 37.7% and 4.4% of patients were treated with csDMARDs and targeted synthetic DMARDs, respectively. Treatment modifications in the previous year were reported by 48.4% of patients, with major reasons being lack of efficacy (38%) and remission or major improvement in the disease (14%).

Study details: Findings are from a retrospective observational cross-sectional study including 316 adults with established PsA and psoriasis who received DMARD treatment for at least 183 days in the previous year.

Disclosures: This work was funded by Bristol Myers Squibb, Germany. Some of the authors declared receiving speaker’s fees and compensation for consultancy or board memberships from Bristol Myers Squibb. Dr. Daamen and Dr. Rothnie declared being current or previous employees of Bristol Myers Squibb.

Source: Behrens F et al. Mod Rheumatol. 2021 Aug 26. doi: 10.1080/14397595.2020.1816597.